Castle Biosciences introduces 487-gene panel to guide JAK inhibitor or Th2 therapy decisions

Castle Biosciences introduces 487-gene panel to guide JAK inhibitor or Th2 therapy decisions
Castle Biosciences unveils immune profiling

Castle Biosciences has unveiled AdvanceAD-Tx, a genetic testing platform that evaluates the expression of 487 genes across 12 separate inflammatory and cutaneous biology pathways.

This tool provides clinicians with one of two actionable molecular profiles—a JAK Inhibitor Responder Profile or a Th2 Molecular Profile—aiming to help medical professionals better understand the underlying immune mechanisms in patients and enhance personalized treatment strategies.

Castle Biosciences’ introduction of AdvanceAD-Tx highlights a broader commitment to precision medicine, building upon prior research demonstrating the company’s i31-SLNB test's sentinel lymph node prediction accuracy in melanoma, as explored in recent coverage. These advancements align with findings that the DecisionDx-Melanoma i31-SLNB platform can identify patients below the 5 percent NCCN threshold for sentinel lymph node biopsy, signaling the firm's sustained focus on expanding molecular diagnostics to refine treatment pathways.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.